Cytarabine
- Generic Name
- Cytarabine
- Brand Names
- Cytosar, Vyxeos
- Drug Type
- Small Molecule
- Chemical Formula
- C9H13N3O5
- CAS Number
- 147-94-4
- Unique Ingredient Identifier
- 04079A1RDZ
- Background
A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
- Indication
For the treatment of acute non-lymphocytic leukemia, acute lymphocytic leukemia and blast phase of chronic myelocytic leukemia.
Cytarabine is indicated in combination with daunorubicin for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in adults and pediatric patients 1 year and older.
- Associated Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia, Acute Myeloid Leukemia With Myelodysplasia-Related Changes, Acute Promyelocytic Leukemia, Meningeal leukemia, Metastatic Malignant Neoplasm to the Leptomeninges, Non-Hodgkin's Lymphoma (NHL), Treatment-Related Acute Myeloid Leukemia, Blast phase Chronic myeloid leukemia
- Associated Therapies
- -
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2024-10-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03983824
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)
- Conditions
- Interventions
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT03964090
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL
- Conditions
- Interventions
- First Posted Date
- 2019-05-24
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- University of Virginia
- Target Recruit Count
- 36
- Registration Number
- NCT03962465
- Locations
- 🇺🇸
University of Wisconsin, Madison, Wisconsin, United States
🇺🇸University of Virginia, Charlottesville, Virginia, United States
🇺🇸Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
- First Posted Date
- 2019-05-23
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- Ciceri Fabio
- Target Recruit Count
- 15
- Registration Number
- NCT03961919
- Locations
- 🇮🇹
Ospedale San Raffaele, Milano, Lombardia, Italy
Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Conditions
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyDrug: Calaspargase PegolProcedure: Bone ScanDrug: CyclophosphamideProcedure: Computed TomographyDrug: Daunorubicin HydrochlorideDrug: DexamethasoneDrug: CytarabineDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumBiological: Inotuzumab OzogamicinDrug: MercaptopurineDrug: MethotrexateDrug: PegaspargaseProcedure: Magnetic Resonance ImagingDrug: PrednisoloneOther: Questionnaire AdministrationRadiation: Radiation TherapyProcedure: Positron Emission TomographyDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-05-22
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 4997
- Registration Number
- NCT03959085
- Locations
- 🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸Michigan State University Clinical Center, East Lansing, Michigan, United States
🇺🇸Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital, Grand Rapids, Michigan, United States
Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2022-10-20
- Lead Sponsor
- Delta-Fly Pharma, Inc.
- Target Recruit Count
- 450
- Registration Number
- NCT03926624
- Locations
- 🇺🇸
University of California, Irvine, California, United States
🇺🇸Decatur Memorial Hospital-Cancer Care Specialists of Central IL, Decatur, Illinois, United States
🇺🇸The University of Mississippi Medical Center, Jackson, Mississippi, United States
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: Asparaginase Erwinia chrysanthemiDrug: CyclophosphamideBiological: BlinatumomabDrug: CytarabineDrug: DexamethasoneDrug: Doxorubicin HydrochlorideDrug: Leucovorin CalciumDrug: MercaptopurineDrug: Mercaptopurine Oral SuspensionDrug: MethotrexateDrug: PegaspargaseRadiation: Radiation TherapyDrug: PrednisoneDrug: PrednisoloneDrug: ThioguanineDrug: Vincristine Sulfate
- First Posted Date
- 2019-04-16
- Last Posted Date
- 2024-12-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 6720
- Registration Number
- NCT03914625
- Locations
- 🇨🇦
IWK Health Centre, Halifax, Nova Scotia, Canada
🇨🇦McMaster Children's Hospital at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇺🇸Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
- First Posted Date
- 2019-04-12
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 32
- Registration Number
- NCT03913559
- Locations
- 🇺🇸
Rady Children's Hospital San Diego, San Diego, California, United States
🇺🇸St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Gentuzumab Ozogamicin and Midostaurin Combination With Standard Cytarabine and Danunorubi Midostaurin as a Novel Approach to Treating Patients With Newly Diagnosed FLT-3 Mutated Acute Myeloid Leukemia
- Conditions
- Interventions
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Uma Borate
- Target Recruit Count
- 18
- Registration Number
- NCT03900949
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy with CPX-351 in Adult Patients with Newly Diagnosed AML and Intermediate- or Adverse Genetics
- Conditions
- Interventions
- First Posted Date
- 2019-04-01
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- University of Ulm
- Target Recruit Count
- 882
- Registration Number
- NCT03897127
- Locations
- 🇩🇪
Klinikum Bremen-Mitte, Bremen, Germany
🇩🇪Klinikum Darmstadt, Darmstadt, Germany
🇩🇪St.-Johannes-Hospital, Dortmund, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.